Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isobutyric acid is a short-chain fatty acid (SCFA) and a naturally occurring metabolite with diverse biological roles. It has been identified as a biomarker in various conditions, including elevated levels in the plasma of patients with Medullary Thyroid Cancer and Lung Cancer Brain Metastasis, and in the saliva of individuals with Laryngopharyngeal Reflux Disease. Isobutyric acid plays a role in regulating gelatinase secretion via NF-κB signaling, contributing to periodontal tissue destruction. Furthermore, microbiota-derived isobutyric acid has been shown to suppress NLRP3 inflammasome overactivation, mediating protective effects against colitis. Its levels are also influenced by probiotic interventions, contributing to the alleviation of autistic-like behaviors and the improvement of intestinal barrier function. Additionally, it exhibits antimicrobial properties as a volatile organic compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isobutyric acid.